+

WO2002018375A1 - Quinazolines, medicaments a effet inhibant la tyrosine-kinase et contenant lesdits composes, leur utilisation et procedes permettant de les produire - Google Patents

Quinazolines, medicaments a effet inhibant la tyrosine-kinase et contenant lesdits composes, leur utilisation et procedes permettant de les produire Download PDF

Info

Publication number
WO2002018375A1
WO2002018375A1 PCT/EP2001/009534 EP0109534W WO0218375A1 WO 2002018375 A1 WO2002018375 A1 WO 2002018375A1 EP 0109534 W EP0109534 W EP 0109534W WO 0218375 A1 WO0218375 A1 WO 0218375A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino
methyl
group
quinazoline
chloro
Prior art date
Application number
PCT/EP2001/009534
Other languages
German (de)
English (en)
Inventor
Frank Himmelsbach
Elke Langkopf
Birgit Jung
Stefan Blech
Flavio Solca
Original Assignee
Boehringer Ingelheim Pharma Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma Gmbh & Co. Kg filed Critical Boehringer Ingelheim Pharma Gmbh & Co. Kg
Priority to MXPA03001484A priority Critical patent/MXPA03001484A/es
Priority to JP2002523890A priority patent/JP2004507537A/ja
Priority to EP01978279A priority patent/EP1322645A2/fr
Priority to AU2002210444A priority patent/AU2002210444A1/en
Priority to CA002417955A priority patent/CA2417955A1/fr
Publication of WO2002018375A1 publication Critical patent/WO2002018375A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to quinazolines of the general formula
  • R a is a benzyl or 1-phenylethyl group or a phenyl group substituted by the radicals R- L and R 2 , where
  • R- L represents a hydrogen, fluorine, chlorine or bromine atom, a methyl, trifluoromethyl, cyan or ethynyl group and R 2 represents a hydrogen or fluorine atom,
  • R b is a -N (CH 2 CO 2 R 3 ) 2 group, where
  • R 3 represents a hydrogen atom, a methyl or ethyl group, an R 4 O-CO-CH 2 -N-CH 2 -CH 2 -OH group optionally substituted on the methylene groups by 1 or 2 methyl or ethyl groups, where
  • R 4 represents a hydrogen atom or a C 1-4 alkyl group
  • n is an integer from 2 to 4,
  • Particularly preferred compounds are the compounds of the general formula I mentioned above in which
  • R a is a 1-phenylethyl group or a phenyl group substituted by the radicals R x and R 2 , where
  • R x represents a fluorine, chlorine or bromine atom, a methyl or ethinyl group and R 2 represents a hydrogen or fluorine atom,
  • R b is a 2-oxomorpholin-4-yl group which is substituted by 1 or 2 methyl or ethyl groups, or
  • n is an integer from the range from 2 to 4, their tautomers, their stereoisomers and their salts.
  • R a is a 1-phenylethyl or 3-chloro-4-fluorophenyl group
  • R b is a 2 -oxo-morpholin-4-yl group which is substituted by 1 or 2 methyl groups
  • n is an integer from the range from 2 to 4,
  • the compounds of the general formula I can be prepared, for example, by the following processes:
  • R a , R b and n are defined as mentioned at the beginning, with a
  • a leaving group such as a halogen atom, for example a chlorine or bromine atom, a vinylcarbonyloxy group or a hydroxyl group.
  • the reaction is optionally carried out in a solvent or solvent mixture such as methylene chloride, dimethylformamide, acetonitrile, toluene, chlorobenzene, tetrahydrofuran, methylene chloride / tetrahydrofuran or dioxane, if appropriate in the presence of an inorganic or organic base and, if appropriate, in the presence of a dehydrating agent at temperatures between -80 and 150 ° C, preferably at temperatures between -60 and 80 ° C.
  • a solvent or solvent mixture such as methylene chloride, dimethylformamide, acetonitrile, toluene, chlorobenzene, tetrahydrofuran, methylene chloride / tetrahydrofuran or dioxane, if appropriate in the presence of an inorganic or organic base and, if appropriate, in the presence of a dehydrating agent at temperatures between -80 and 150 ° C, preferably at temperatures between -60 and 80
  • the reaction is optionally carried out in a solvent or solvent mixture such as methylene chloride, dimethylformamide, acetonitrile, toluene, chlorobenzene, tetrahydrofuran, methylene chloride / tetrahydrofuran or dioxane in the presence of a tertiary organic base such as triethylamine or N-ethyl-diisopropylamine (Hünig base), these organic bases can also serve as solvents at the same time, or in the presence of an inorganic base such as sodium carbonate, potassium carbonate or sodium hydroxide preferably at temperatures between -80 and 150 ° C, preferably at temperatures between -60 and 80 ° C.
  • a solvent or solvent mixture such as methylene chloride, dimethylformamide, acetonitrile, toluene, chlorobenzene, tetrahydrofuran, methylene chloride / tetrahydrofuran or dioxane
  • the reaction is preferably carried out in the presence of a dehydrating agent, for example in the presence of isobutyl chloroformate, thionyl chloride, trimethylchlorosilane, phosphorus trichloride, phosphorus pentoxide, hexamethyldisilazane, N, N ' -Dicyclohexylcarbodiimid, N, N '-Dicyclohexyl-carbodiimide / N-hydroxysuccinimide or 1-hydroxy-benzotriazole and optionally additionally in the presence of 4-dimethylamino-pyridine, N, N' -carbonyldiimidazole or triphenylphosphine / tetra-chlorocarbon as appropriate in a carbon Methylene chloride, tetrahydrofuran, dioxane, toluene, chlorobenzene, dimethyl
  • reaction is carried out particularly advantageously with acrylic acid and acrylic acid chloride in the presence of triethylamine.
  • any reactive groups present such as hydroxyl, carboxy or imino groups, can be protected during the reaction by customary protective groups, which are split off again after the reaction.
  • the trimethylsilyl, acetyl, benzoyl, methyl, ethyl, tert-butyl, trityl, benzyl or tetrahydropyranyl group comes as a protective radical for a hydroxyl group
  • the formyl, acetyl, trifluoroacetyl, ethoxycarbonyl, tert. butoxycarbonyl, benzyloxycarbonyl, benzyl, methoxybenzyl or 2,4-ethoxybenzyl group are considered.
  • the subsequent subsequent splitting off of a protective radical used takes place, for example, hydrolytically in an aqueous solvent, for example in water, isopropanol / water, acetic acid / water, tetrahydrofuran / water or dioxane / water, in the presence of an acid such as trifluoroacetic acid, hydrochloric acid or sulfuric acid or in the presence of an alkali base such as sodium hydroxide or potassium hydroxide or aprotic, for example in Presence of iodotrimethylsilane, at temperatures between 0 and 120 ° C, preferably at temperatures between 10 and 100 ° C.
  • an aqueous solvent for example in water, isopropanol / water, acetic acid / water, tetrahydrofuran / water or dioxane / water, in the presence of an acid such as trifluoroacetic acid, hydrochloric acid or sulfuric acid or in the presence of an alkali base such as sodium
  • a benzyl, methoxybenzyl or benzyloxycarbonyl radical is split off, for example by hydrogenolysis, e.g. with hydrogen in the presence of a catalyst such as palladium / carbon in a suitable solvent such as methanol, ethanol, ethyl acetate or glacial acetic acid, optionally with the addition of an acid such as hydrochloric acid at temperatures between 0 and 100 ° C, but preferably at room temperatures between 20 and 60 ° C, and at a hydrogen pressure of 1 to 7 bar, but preferably from 3 to 5 bar.
  • a 2,4-dimethoxybenzyl radical is preferably cleaved in trifluoroacetic acid in the presence of anisole.
  • a tert-butyl or tert-butyloxycarbonyl radical is preferably cleaved off by treatment with an acid such as trifluoroacetic acid or hydrochloric acid or by treatment with iodotrimethylsilane, optionally using a solvent such as methylene chloride, dioxane, methanol or diethyl ether.
  • a trifluoroacetyl radical is preferably split off by treatment with an acid such as hydrochloric acid, if appropriate in the presence of a solvent such as acetic acid at temperatures between 50 and 120 ° C. or by treatment with sodium hydroxide solution optionally in the presence of a solvent such as tetrahydrofuran at temperatures between 0 and 50 ° C.
  • the compounds of general formula I obtained can be separated into their enantiomers and / or diastereomers.
  • ice / trans mixtures can be separated into their ice and trans isomers, and compounds with at least one optically active carbon atom can be separated into their enantiomers.
  • the cis / trans mixtures obtained can be chromatographed into their eis and trans isomers, the compounds of general formula I obtained which occur in racemates, according to methods known per se (see Allinger NL and Eliel EL in "Topics in Stereochemistry", Vol.
  • the separation of enantiomers is preferably carried out by column separation on chiral phases or by recrystallization from an optically active solvent or by reaction with a salt or derivative such as e.g. Optically active substance which forms esters or amides, in particular acids and their activated derivatives or alcohols, and separation of the diastereomeric salt mixture or derivative obtained in this way, e.g. due to different solubilities, it being possible for the free antipodes to be released from the pure diastereomeric salts or derivatives by the action of suitable agents.
  • a salt or derivative such as e.g. Optically active substance which forms esters or amides, in particular acids and their activated derivatives or alcohols
  • (+) - or (-) menthol comes as optically active alcohol and as optically active
  • the compounds of the formula I obtained can be converted into their salts, in particular for pharmaceutical use into their physiologically tolerable salts with inorganic or organic acids.
  • acids for example hydrochloric acid, hydrobromic acid, sulfuric acid, methanesulfonic acid, phosphoric acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid or maleic acid.
  • the compounds of the general formula I according to the invention and their physiologically tolerated salts have valuable pharmacological properties, in particular an inhibitory effect on the signal transduction mediated by the epidermal growth factor receptor (EGF-R), this being achieved, for example, by inhibiting the Ligand binding, the receptor dimerization or the tyrosine kinase itself can be effected. It is also possible that the signal transmission on further downstream components may be blocked.
  • EGF-R epidermal growth factor receptor
  • EGF-R-mediated signal transmission can be demonstrated, for example, with cells which express human EGF-R and whose survival and proliferation depend on stimulation by EGF or TGF-alpha.
  • An interleukin-3 (IL-3) -dependent cell line of murine origin was used here which has been genetically modified in such a way that it expresses functional human EGF-R.
  • the proliferation of these cells called F / L-HERc can therefore be stimulated either by murine IL-3 or by EGF (see von Rüden, T. et al. In EMBO J. 2, 2749-2756 (1988) and Pierce, JH et al. in Science 2__9_, 628-631 (1988)).
  • the FDC-Pi ⁇ cell line was used as the starting material for the F / L-HERc cells. Their production by Dexter, TM et al. in J. Exp. Med. 152, 1036-1047 (1980). Alternatively, however, other growth factor-dependent cells can also be used (see, for example, Pierce, JH et al. In Science 2.3.2, 628-631 (1988), Shibuya, H. et al. In Cell 2JQ_, 57-67 ( 1992) and Alexander, WS et al. In EMBO J. Lu, 3683-3691 (1991)). Recombinant retroviruses were used to express the human EGF-R cDNA (see Ullrich, A. et al.
  • F / L-HERc cells were in RPMI / 1640 medium (BioWhittaker), supplemented with 10% fetal bovine serum (FCS, Boehringer Mannheim), 2 mM glutamine (BioWhittaker), standard antibiotics and 20 ng / ml human EGF (Promega), at 37 ° C and 5% CO 2 cultivated.
  • FCS fetal bovine serum
  • FCS Boehringer Mannheim
  • 2 mM glutamine BioWhittaker
  • standard antibiotics 20 ng / ml human EGF (Promega)
  • 20 ng / ml human EGF Promega
  • the compounds according to the invention were dissolved in 100% dimethyl sulfoxide (DMSO) and added to the cultures in various dilutions, the maximum DMSO concentration being 1%. The cultures were incubated at 37 ° C for 48 hours. To determine the inhibitory activity of the compounds according to the invention, the relative cell number was determined using the Cell
  • the compounds of the general formula I according to the invention thus inhibit signal transduction by tyrosine kinases, as has been shown using the example of the human EGF receptor, and are therefore useful for the treatment of pathophysiological processes which are caused by overactive tyrosine kinases.
  • tyrosine kinases e.g. benign or malignant tumors, in particular tumors of epithelial and neuroepithelial origin, metastasis and the abnormal proliferation of vascular endothelial cells (neoangiogenesis).
  • the compounds of the invention are also useful for the prevention and treatment of respiratory and lung diseases associated with increased or altered mucus production caused by stimulation of tyrosine kinases such as e.g. for inflammatory diseases of the respiratory tract such as chronic bronchitis, chronic obstructive bronchitis, asthma, bronchiectasis, allergic or non-allergic rhinitis or sinusitis, cystic fibrosis, l-antitrypsin deficiency, or for cough, pulmonary emphysema, pulmonary fibrosis and hyperreactive respiratory tract.
  • tyrosine kinases such as e.g. for inflammatory diseases of the respiratory tract such as chronic bronchitis, chronic obstructive bronchitis, asthma, bronchiectasis, allergic or non-allergic rhinitis or sinusitis, cystic fibrosis, l-antitrypsin deficiency, or for cough, pulmonary em
  • the compounds are also suitable for the treatment of diseases of the gastrointestinal tract and bile ducts and - bladder that is associated with impaired activity of the tyrosine kinases, such as those found in chronic inflammatory changes, such as cholecystitis, Crohn's disease, ulcerative colitis, and ulcers in the gastrointestinal tract or as in gastrointestinal disorders Tracts that are associated with increased secretion, such as M. Menetrier, secreting adenomas and protein loss syndromes,
  • nasal polyps as well as of polyps of the gastrointestinal tract of different genesis such as e.g. villous or adenomatous polyps of the large intestine, but also of polyps in familial polyposis coli, in intestinal polyps as part of the Gardner syndrome, in polyps in the entire gastrointestinal tract in Peutz-Jeghers syndrome, in inflammatory pseudopolypes, in juvenile polyps , with colitis cystica profunda and with Pneumatosis cystoides intestinales.
  • different genesis such as e.g. villous or adenomatous polyps of the large intestine, but also of polyps in familial polyposis coli, in intestinal polyps as part of the Gardner syndrome, in polyps in the entire gastrointestinal tract in Peutz-Jeghers syndrome, in inflammatory pseudopolypes, in juvenile polyps , with colitis cystica profunda and with Pneumatosis cystoides intestinales.
  • kidney diseases in particular in the case of cystic changes such as in cystic kidneys
  • kidney cysts which may be of idiopathic origin or occur in the context of syndromes such as e.g. in tuberous sclerosis, in von Hippel-Lindau syndrome, in nephronophthisis and marrow sponge kidney as well as other diseases which are caused by aberrant function of tyrosine kinases, e.g. epidermal hyperproliferation (psoriasis), inflammatory processes, diseases of the immune system, hyperproliferation of hematopoietic cells etc.
  • psoriasis epidermal hyperproliferation
  • the compounds according to the invention can be used alone or in combination with other pharmacologically active compounds, for example in tumor therapy in monotherapy or in combination with other anti-tumor therapeutic agents, for example in combination with topoisomerase inhibitors (for example etoposide) , Mitosis inhibitors (e.g. vinblastine), with nucleic acid interacting compounds (e.g. cis-platinum, cyclophosphamide, adriamycin), hormone antagonists (e.g. tamoxifen), inhibitors of metabolic processes (e.g. 5-FU etc), cytokines (e.g. interferons), antibodies etc.
  • topoisomerase inhibitors for example etoposide
  • Mitosis inhibitors e.g. vinblastine
  • nucleic acid interacting compounds e.g. cis-platinum, cyclophosphamide, adriamycin
  • hormone antagonists e.g. tamoxifen
  • these compounds are used alone or in combination with other respiratory therapeutic agents such as secretolytic, broncholytic and / or anti-inflammatory substances.
  • these compounds may also be used alone or in combination with moti- lticians- or secretion influencing or inflammatory ⁇ inhibiting substances are given. These combinations can be administered either simultaneously or sequentially.
  • Combination with other active substances can take place intravenously, subcutaneously, intramuscularly, intrarectally, intraperitoneally, intranasally, by inhalation or transdermally or orally, aerosol formulations being particularly suitable for> inhalation.
  • the compounds according to the invention are generally used in warm-blooded vertebrates, in particular in humans, in doses of 0.01-100 mg / kg body weight, preferably 0.1-15 mg / kg.
  • these are mixed with one or more conventional inert carriers and / or diluents, e.g.
  • the residue is stirred with plenty of ethyl acetate, washed with a little cold water and saturated sodium chloride solution, dried over magnesium sulfate and concentrated. Since a mixture of open-chain and already cyclized product is evidently formed, the resinous residue is refluxed with 0.08 ml of acetyl chloride in 40 ml of ethanol for about 30 minutes. The mixture is then concentrated and toluene is added to the residue. The solvent is distilled off and the flask residue is suspended in methylene chloride, mixed with a little ice water and made alkaline with 1 ml of 4N sodium hydroxide solution. The organic phase is separated off, dried over magnesium sulfate and concentrated.
  • the organic phase is washed with water and saturated sodium chloride solution and remains overnight at room temperature, a yellow precipitate being formed. This is suctioned off, washed with ethyl acetate and dried. The filtrate is concentrated and the evaporation residue recrystallized from ethyl acetate. The crystals obtained in this way are combined with the precipitate which has been suctioned off and recrystallized again from ethyl acetate. The desired product is obtained in the form of pale yellow crystals.
  • the substance is obtained in 65% yield by hydrogenation of 4- [(3-chloro-4-fluorophenyl) amino] -7- [3- (5, 5-dimethyl-2-oxomorpholin-4-yl) - propyloxy] -6-nitro-quinazoline in tetrahydrofuran in the presence of Raney nickel in a Parr apparatus at a hydrogen partial pressure of 50 psi.
  • 1 coated tablet contains: Active substance 75.0 mg
  • the active substance is mixed with calcium phosphate, corn starch, polyvinylpyrrolidone, hydroxypropylmethyl cellulose and half of the stated amount of magnesium stearate. Pressings with a diameter of approx. 13 mm are produced on a tabletting machine, these are rubbed on a suitable machine through a sieve with a 1.5 mm mesh size and mixed with the remaining amount of magnesium stearate. This granulate is pressed on a tablet machine into tablets of the desired shape.
  • the dragee cores thus produced are coated with a film consisting essentially of hydroxypropylmethyl cellulose.
  • the finished film coated tablets are polished with beeswax. : Coated weight: 245 mg.
  • Composition 1 tablet contains:
  • Active ingredient, milk sugar and starch are mixed and moistened uniformly with an aqueous solution of the polyvinylpyrrolidone. After screening the moist mass (2.0 mm mesh size) and drying in a rack drying cabinet at 50 ° C, sieving is again carried out (1.5 mm mesh size) and the lubricant is added. The ready-to-press mixture is processed into tablets. Tablet weight: 220 mg
  • Diameter 10 mm, biplane with facet on both sides and partial notch on one side.
  • 1 tablet contains: active substance 150.0 mg
  • the active substance mixed with milk sugar, corn starch and silica is moistened with a 20% aqueous polyvinylpyrrolidone solution and passed through a sieve with a mesh size of 1.5 mm.
  • 1 capsule contains:
  • the active ingredient is mixed with the excipients, passed through a sieve with a mesh size of 0.75 mm and mixed homogeneously in a suitable device.
  • the final mix is filled into size 1 hard gelatin capsules.
  • Capsule filling approx. 320 mg capsule shell: hard gelatin capsule size 1.
  • 1 suppository contains:
  • Polyethylene glycol 1500 550.0 mg
  • the active ingredient is homogeneously distributed therein and the melt is poured into pre-cooled molds.
  • the melt is poured into pre-cooled molds.
  • Carboxymethylcellulose Na salt 0.10 g methyl p-hydroxybenzoate 0.05 g propyl p-hydroxybenzoate 0.01 g cane sugar 10.00 g
  • Dest. Water is heated to 70 ° C. P-Hydroxybenzoic acid methyl ester and propyl ester as well as glycerol and carboxymethyl cellulose sodium salt are dissolved therein with stirring. It is cooled to room temperature and the active ingredient is added with stirring and dispersed homogeneously. According were to admit and ⁇ dissolving the sugar, the sorbitol solution and the flavoring, the suspension is evacuated with stirring for deaeration.
  • 5 ml of suspension contain 50 mg of active ingredient.
  • the active substance is dissolved in the required amount of 0.01N HCl, made isotonic with sodium chloride, sterile filtered and filled into 2 ml ampoules.
  • composition active ingredient 50.0 mg
  • the active substance is dissolved in the required amount of 0.01N HCl, made isotonic with sodium chloride, sterile filtered and filled into 10 ml ampoules.
  • 1 capsule contains:
  • the active substance is mixed with lactose for inhalation purposes.
  • the mixture is filled into capsules on a capsule machine (weight of the empty capsule approx. 50 mg).
  • 1 hub includes:
  • the active substance and benzalkonium chloride are dissolved in ethanol / water (50/50).
  • the pH of the solution is adjusted with 1N hydrochloric acid.
  • the adjusted solution is filtered and filled into containers (cartridges) suitable for the hand-held nebuliser.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne des quinazolines de formule générale (I) dans laquelle Ra,Rb et n ont la signification mentionnée dans la revendication 1, leurs tautomères, leurs stéréoisomères et leurs sels, notamment leurs sels physiologiquement tolérables avec des acides ou des bases inorganiques ou organiques, qui présentent des propriétés pharmacologiques intéressantes, en particulier un effet inhibiteur sur la transduction de signaux induite par tyrosine-kynases. L'invention concerne en outre l'utilisation desdits composés pour traiter des affections, en particulier des affections tumorales, des affections des poumons et des voies respiratoires, ainsi que leur mode de production.
PCT/EP2001/009534 2000-08-26 2001-08-18 Quinazolines, medicaments a effet inhibant la tyrosine-kinase et contenant lesdits composes, leur utilisation et procedes permettant de les produire WO2002018375A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
MXPA03001484A MXPA03001484A (es) 2000-08-26 2001-08-18 Quinazolinas, medicamentos que contienen estos compuestos, y son efectivos como inhbidores de tirosina quinasa, su utilizacion y metodos para su produccion.
JP2002523890A JP2004507537A (ja) 2000-08-26 2001-08-18 キナゾリン化合物、この化合物を含有する医薬組成物、その使用及びその調製方法
EP01978279A EP1322645A2 (fr) 2000-08-26 2001-08-18 Quinazolines, medicaments a effet inhibant la tyrosine-kinase et contenant lesdits composes, leur utilisation et procedes permettant de les produire
AU2002210444A AU2002210444A1 (en) 2000-08-26 2001-08-18 Quinazolines, medicaments, which contain these compounds and which are effectiveas tyrosine kinase inhibitors, their use, and methods for the production thereo f
CA002417955A CA2417955A1 (fr) 2000-08-26 2001-08-18 Quinazolines, compositions pharmaceutiques comprenant ces composes, leur utilisation et procedes permettant de les produire

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10042064A DE10042064A1 (de) 2000-08-26 2000-08-26 Chinazoline, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE10042064.8 2000-08-26

Publications (1)

Publication Number Publication Date
WO2002018375A1 true WO2002018375A1 (fr) 2002-03-07

Family

ID=7653950

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/009534 WO2002018375A1 (fr) 2000-08-26 2001-08-18 Quinazolines, medicaments a effet inhibant la tyrosine-kinase et contenant lesdits composes, leur utilisation et procedes permettant de les produire

Country Status (7)

Country Link
EP (1) EP1322645A2 (fr)
JP (1) JP2004507537A (fr)
AU (1) AU2002210444A1 (fr)
CA (1) CA2417955A1 (fr)
DE (1) DE10042064A1 (fr)
MX (1) MXPA03001484A (fr)
WO (1) WO2002018375A1 (fr)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005526123A (ja) * 2002-05-11 2005-09-02 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 良性前立腺過形成（ｂｐｈ）／前立腺肥大症の治療のためのｅｇｆｒ媒介シグナル伝達のインヒビターの使用
JP2006522753A (ja) * 2003-04-10 2006-10-05 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング インスリン抵抗性症候群に関連する疾患の治療に有用なアミンを分割するための方法
WO2007055513A1 (fr) * 2005-11-08 2007-05-18 Hanmi Pharm. Co., Ltd. Dérivés de quinazoline en tant qu'inhibiteurs de transduction de signal et méthode de synthèse desdits dérivés
WO2007055514A1 (fr) * 2005-11-08 2007-05-18 Hanmi Pharm. Co., Ltd. Dérivés de quinazoline en tant qu'inhibiteurs multiplex et méthode de synthèse desdits dérivés
USRE43431E1 (en) 2000-12-20 2012-05-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
US8507502B2 (en) 2008-11-10 2013-08-13 National Health Research Institutes Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors
US8722694B2 (en) 1999-06-21 2014-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
US8877764B2 (en) 2006-09-18 2014-11-04 Boehringer Ingelheim International Gmbh Method for treating cancer harboring EGFR mutations
US9089571B2 (en) 2005-11-11 2015-07-28 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
US9545381B2 (en) 2009-07-06 2017-01-17 Boehringer Ingelheim International Gmbh Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
US10487091B2 (en) 2015-10-05 2019-11-26 The Trustees Of Columbia University In The City Of New York Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997038983A1 (fr) * 1996-04-12 1997-10-23 Warner-Lambert Company Inhibiteurs irreversibles de tyrosine kinases
WO1999006378A1 (fr) * 1997-07-29 1999-02-11 Warner-Lambert Company Inhibiteurs irreversibles de tyrosines kinases
WO2000031048A1 (fr) * 1998-11-19 2000-06-02 Warner-Lambert Company N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholine-4-yle-propoxy)-quinazoline-6-yle]-acrylamide, un inhibiteur irreversible des tyrosine kinases
WO2000051991A1 (fr) * 1999-02-27 2000-09-08 Boehringer Ingelheim Pharma Kg Derives de 4-amino-quinazoline et de quinoline ayant un effet inhibiteur sur la transduction de signal par les tyrosine kinases

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997038983A1 (fr) * 1996-04-12 1997-10-23 Warner-Lambert Company Inhibiteurs irreversibles de tyrosine kinases
WO1999006378A1 (fr) * 1997-07-29 1999-02-11 Warner-Lambert Company Inhibiteurs irreversibles de tyrosines kinases
WO2000031048A1 (fr) * 1998-11-19 2000-06-02 Warner-Lambert Company N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholine-4-yle-propoxy)-quinazoline-6-yle]-acrylamide, un inhibiteur irreversible des tyrosine kinases
WO2000051991A1 (fr) * 1999-02-27 2000-09-08 Boehringer Ingelheim Pharma Kg Derives de 4-amino-quinazoline et de quinoline ayant un effet inhibiteur sur la transduction de signal par les tyrosine kinases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SMAILL, JEFF B. ET AL: "Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(Phenylamino)quinazoline- and 4-(Phenylamino)pyrido[3,2- d]pyrimidine-6-acrylamides bearing additional solubilizing functions", J. MED. CHEM. (2000), 43(7), 1380-1397, XP002187455 *

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8722694B2 (en) 1999-06-21 2014-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
US8586608B2 (en) 2000-12-20 2013-11-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
USRE43431E1 (en) 2000-12-20 2012-05-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
JP2005526123A (ja) * 2002-05-11 2005-09-02 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 良性前立腺過形成（ｂｐｈ）／前立腺肥大症の治療のためのｅｇｆｒ媒介シグナル伝達のインヒビターの使用
JP4836778B2 (ja) * 2003-04-10 2011-12-14 ポクセル ソシエテ パール アクシオン サンプリフィエ インスリン抵抗性症候群に関連する疾患の治療に有用なアミンを分割するための方法
JP2006522753A (ja) * 2003-04-10 2006-10-05 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング インスリン抵抗性症候群に関連する疾患の治療に有用なアミンを分割するための方法
JP4918097B2 (ja) * 2005-11-08 2012-04-18 ハンミ ファーム． シーオー．， エルティーディー． 多重阻害剤としてのキナゾリン誘導体及びその製造方法
WO2007055514A1 (fr) * 2005-11-08 2007-05-18 Hanmi Pharm. Co., Ltd. Dérivés de quinazoline en tant qu'inhibiteurs multiplex et méthode de synthèse desdits dérivés
WO2007055513A1 (fr) * 2005-11-08 2007-05-18 Hanmi Pharm. Co., Ltd. Dérivés de quinazoline en tant qu'inhibiteurs de transduction de signal et méthode de synthèse desdits dérivés
JP2009514947A (ja) * 2005-11-08 2009-04-09 ハンミ ファーム． シーオー．， エルティーディー． 多重阻害剤としてのキナゾリン誘導体及びその製造方法
US9089571B2 (en) 2005-11-11 2015-07-28 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
US9539258B2 (en) 2005-11-11 2017-01-10 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
US8877764B2 (en) 2006-09-18 2014-11-04 Boehringer Ingelheim International Gmbh Method for treating cancer harboring EGFR mutations
US8507502B2 (en) 2008-11-10 2013-08-13 National Health Research Institutes Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors
US10004743B2 (en) 2009-07-06 2018-06-26 Boehringer Ingelheim International Gmbh Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
US9545381B2 (en) 2009-07-06 2017-01-17 Boehringer Ingelheim International Gmbh Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
US10487091B2 (en) 2015-10-05 2019-11-26 The Trustees Of Columbia University In The City Of New York Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies
US10865214B2 (en) 2015-10-05 2020-12-15 The Trustees of Columbia University in they City of New York Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies
US11008341B2 (en) 2015-10-05 2021-05-18 The Trustees Of Columbia University In The City Of New York Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies
US11230558B2 (en) 2015-10-05 2022-01-25 The Trustees Of Columbia University In The City Of New York Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies
US11261199B2 (en) 2015-10-05 2022-03-01 The Trustees Of Columbia University In The City Of New York Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies

Also Published As

Publication number Publication date
DE10042064A1 (de) 2002-03-07
JP2004507537A (ja) 2004-03-11
EP1322645A2 (fr) 2003-07-02
MXPA03001484A (es) 2003-06-06
CA2417955A1 (fr) 2003-01-30
AU2002210444A1 (en) 2002-03-13

Similar Documents

Publication Publication Date Title
EP1315718B1 (fr) Heterocycles bicycliques, medicaments contenant lesdits composes, leur utilisation et procedes permettant de les produire
EP1731511B1 (fr) Heterocycles bicycliques, medicaments contenant ces composés, leur utilisation et procédés permettant de les préparer
DE60022866T2 (de) Bizyklische heterozyklen, diese verbindungen enthaltende zusammenstellungen und verfahren zu deren herstellung
EP1315720B1 (fr) Heterocycles bicycliques, medicaments contenant lesdits composes, leur utilisation et procedes permettant de les produire
WO2002018351A1 (fr) Heterocycles bicycliques, medicaments contenant lesdits composes, leur utilisation et procedes permettant de les produire
WO2002018373A1 (fr) Derives de quinazoline, medicaments contenant lesdits composes, leur utilisation et procedes permettant de les produire
EP1345910B9 (fr) Derives de la quinazoline, medicaments contenant ces composes, leur utilisation et leur procede de fabrication
EP1280798B1 (fr) Heterocycles bicycliques, medicaments contenant ces composes, leur utilisation et leur procede de production
WO2002018370A1 (fr) Heterocycles bicycliques, medicaments contenant lesdits composes, leur utilisation et procedes permettant de les produire
WO2007068552A1 (fr) Heterocycles bicycliques, medicaments contenant ces composes, utilisation et procede de fabrication de ceux-ci
EP1597240B1 (fr) Heterocycles bicycliques, medicaments les contenant, leur utilisation et leurs procedes de production
EP1921070A1 (fr) heterocycles bicycliques, medicaments á base de ces composes, leur usage et procédé pour leur preparation
WO2004108664A2 (fr) Heterocycles bicycliques, medicaments contenant ces composes, leur utilisation et procede pour leur production
WO2002018375A1 (fr) Quinazolines, medicaments a effet inhibant la tyrosine-kinase et contenant lesdits composes, leur utilisation et procedes permettant de les produire
EP2118075A1 (fr) Hétérocycles bicycliques, agents pharmaceutiques contenant ces composés, leur utilisation et leur procédé de préparation
DE10017539A1 (de) Bicyclische Heterocyclen, diese Verbingungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE19908567A1 (de) Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE19911366A1 (de) Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE10040525A1 (de) Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE10023085A1 (de) Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE19954816A1 (de) Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2417955

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001978279

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/001484

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2002523890

Country of ref document: JP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001978279

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001978279

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载